Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative systemic therapy plus CRS-HIPEC for resectable colorectal peritoneal metastases
ISRCTN15977568Phase 3Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, bevacizumab, fluorouracil, folinic acid and 2 more in colorectal cancer (CRC) and peritoneal carcinomatosis (PC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Feasibility of accrual, Complete CRS-HIPEC rate and 9 more. Started Jun 2017; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatinbevacizumabfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ISRCTN15977568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15977568.